The insulin receptor (IR) is a prototypical receptor tyrosine kinase that orchestrates critical cellular processes, including metabolism, cell growth and differentiation. Activation of the IR involves ...

In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK–, the pooled HR ...

Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...

Assessment of sociodemographic disparities in outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE. This is an ASCO Meeting Abstract from the ...

Pfizer (PFE) announced results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor Tukysa as part of an investigational ...